A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

The MEDI8852 phase 2a study will evaluate the safety and tolerability of a single intravenous
(IV) dose of MEDI8852 administered in conjunction with oseltamivir, the safety and
tolerability of oseltamivir alone and the safety and tolerability of a single IV dose of
MEDI8852 alone in adult participants with confirmed acute, uncomplicated influenza caused by
Type A strains. Enrollment is planned in the United States, South Africa, and Australia.

Inclusion Criteria:

- Age 18 through 65 years at the time of screening.

- Symptomatic presumptive Influenza A infection with onset of symptoms less than or
equal to (≤) 5 days prior to MEDI8852 administration and defined as the presence of:

- Fever of greater than or equal to (≥) 38.0 degrees Celsius (100.4 degrees Fahrenheit)
at screening AND

- ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or
fatigue) AND

- ≥ 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)

- Influenza A infection confirmed with positive rapid antigen test

- Able to complete the follow-up period through Day 101 as required by protocol
(including telephone follow-up for Days 11 to 101)

- Females of childbearing potential who are sexually active with a nonsterilized male
partner must use a highly effective method of contraception for at least 2 days prior
to the first dose of investigational product and must agree to continue using such
precautions through Day 101 of the study

Exclusion Criteria:

- Hospitalized subjects.

- Receipt of influenza antiviral therapy within the preceding 14 days.

- Receipt of immunoglobulin or blood products within 6 months prior to screening.

- Known immunodeficiency due to illness, including human immunodeficiency virus (HIV),
or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of
prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months
prior to screening.

- Current clinical evidence of pneumonia.

- Active bacterial infection requiring treatment with oral or parenteral antibiotics.

- History of malignancy other than treated non-melanoma skin cancers or locally-treated
cervical cancer in previous 3 years.

- Any planned surgical procedure before completion of Day 101.